Focused On-demand Library for Nuclear pore complex protein Nup153

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P49790

UPID:

NU153_HUMAN

Alternative names:

153 kDa nucleoporin; Nucleoporin Nup153

Alternative UPACC:

P49790; B4DIK2; E7EPX5; F6QR24; Q4LE47; Q5T9I7; Q7Z743

Background:

Nuclear pore complex protein Nup153, also known as 153 kDa nucleoporin, plays a pivotal role in the nuclear pore complex (NPC). It is essential for nucleocytoplasmic transport, mediating the trafficking of proteins and mRNAs across the nuclear envelope. Nup153 functions as a scaffolding element, crucial for the retention of unspliced mRNAs and the nuclear export of specific mRNA species. It also facilitates the anchoring of TPR to the nuclear membrane, potentially acting as a DNA-binding subunit within the NPC.

Therapeutic significance:

Understanding the role of Nuclear pore complex protein Nup153 could open doors to potential therapeutic strategies.